These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 33755971)
21. Design, Synthesis, And Evaluation Of Cyanopyridines As Anti-Colorectal Cancer Agents Via Inhibiting STAT3 Pathway. Xu L; Shi L; Qiu S; Chen S; Lin M; Xiang Y; Zhao C; Zhu J; Shen L; Zuo Z Drug Des Devel Ther; 2019; 13():3369-3381. PubMed ID: 31576111 [TBL] [Abstract][Full Text] [Related]
22. A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway. Noori S; Nourbakhsh M; Farzaneh S; Zarghi A Anticancer Agents Med Chem; 2020; 20(18):2285-2292. PubMed ID: 32767949 [TBL] [Abstract][Full Text] [Related]
23. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Xiong H; Zhang ZG; Tian XQ; Sun DF; Liang QC; Zhang YJ; Lu R; Chen YX; Fang JY Neoplasia; 2008 Mar; 10(3):287-97. PubMed ID: 18320073 [TBL] [Abstract][Full Text] [Related]
25. Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer. Liu C; Pan Z; Chen Q; Chen Z; Liu W; Wu L; Jiang M; Lin W; Zhang Y; Lin W; Zhou R; Zhao L J Exp Clin Cancer Res; 2021 Sep; 40(1):297. PubMed ID: 34551797 [TBL] [Abstract][Full Text] [Related]
26. The HOTAIR/miR-214/ST6GAL1 crosstalk modulates colorectal cancer procession through mediating sialylated c-Met via JAK2/STAT3 cascade. Liu B; Liu Q; Pan S; Huang Y; Qi Y; Li S; Xiao Y; Jia L J Exp Clin Cancer Res; 2019 Nov; 38(1):455. PubMed ID: 31694696 [TBL] [Abstract][Full Text] [Related]
27. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo. Liu Z; Wang H; Guan L; Lai C; Yu W; Lai M Br J Pharmacol; 2020 Jan; 177(2):298-313. PubMed ID: 31499589 [TBL] [Abstract][Full Text] [Related]
28. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway. Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185 [TBL] [Abstract][Full Text] [Related]
29. A novel small molecular STAT3 inhibitor, 5Br-6b, induces apoptosis and inhibits migration in colorectal cancer cells. Liu Z; Wang H; Guan L; Chen S; Lai M Anticancer Drugs; 2018 Jun; 29(5):402-410. PubMed ID: 29438179 [TBL] [Abstract][Full Text] [Related]
30. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer. Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423 [TBL] [Abstract][Full Text] [Related]
31. Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells. Han S; Jeong AJ; Yang H; Bin Kang K; Lee H; Yi EH; Kim BH; Cho CH; Chung JW; Sung SH; Ye SK J Ethnopharmacol; 2016 Dec; 194():83-90. PubMed ID: 27566200 [TBL] [Abstract][Full Text] [Related]
32. LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis. Wang H; Liu Z; Guan L; Li J; Chen S; Yu W; Lai M Pharmacol Res; 2020 Mar; 153():104661. PubMed ID: 31982491 [TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. Morgillo F; Martinelli E; Troiani T; Orditura M; De Vita F; Ciardiello F PLoS One; 2011; 6(12):e28841. PubMed ID: 22174910 [TBL] [Abstract][Full Text] [Related]
34. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells. Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126 [TBL] [Abstract][Full Text] [Related]
35. Phlorizin from sweet tea inhibits the progress of esophageal cancer by antagonizing the JAK2/STAT3 signaling pathway. Jia Z; Xie Y; Wu H; Wang Z; Li A; Li Z; Yang Z; Zhang Z; Xing Z; Zhang X Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036398 [TBL] [Abstract][Full Text] [Related]
37. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity. Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683 [TBL] [Abstract][Full Text] [Related]
38. Nobiletin inhibits viability of human renal carcinoma cells via the JAK2/STAT3 and PI3K/Akt pathway. Xu Z; Wu D; Fu D; Tang C; Ge J; Zhang Z; Zhou W Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):199-203. PubMed ID: 33040836 [TBL] [Abstract][Full Text] [Related]
39. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation. Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828 [TBL] [Abstract][Full Text] [Related]
40. Salidroside suppresses the growth and invasion of human osteosarcoma cell lines MG63 and U2OS in vitro by inhibiting the JAK2/STAT3 signaling pathway. Huang L; Huang Z; Lin W; Wang L; Zhu X; Chen X; Yang S; Lv C Int J Oncol; 2019 Jun; 54(6):1969-1980. PubMed ID: 31081055 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]